It’s partly true.
There will still be innovation where the government hasn’t figured out how to pressure the market with generics (biologic drugs), or there are politically powerful patient advocacy groups (e.g. oncology, Parkinson’s, Alzheimer’s).
Yes, the US health system will become more like Europe’s regardless of whether Obamacare is repealed.
The question is whether we become like the Netherlands (pretty good), or like the UK or Poland (can you say “snuff party”?)
The wheels are coming off the generic solution. With manufacturing resources scarce, the owners of the businesses just pull production of meds that patients have taken for years but are relatively unprofitable. When the demand is sufficient for the desired price rise to occur, they reappear. It’s a good business model, heh?